Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [3] Core Viewpoints - The chemical pharmaceutical sector has shown the highest growth among sub-sectors, driven by expectations around "centralized procurement optimization discussions" and the "Class B medical insurance catalog" [8] - The trade war environment is expected to enhance the market share of domestic blood products and high-end medical devices due to increased costs of foreign imports [8] - The report suggests a cautious approach for April, focusing on specific segments that may benefit from the trade war, such as domestic blood products and high-end medical devices [8] Summary by Sections Industry Weekly Viewpoints - The pharmaceutical and biotechnology sector's weekly return was 1.20%, outperforming the CSI 300 by 2.57%, ranking 3rd among 31 primary sub-indices [7] - The chemical pharmaceutical sub-sector had the highest weekly growth of 3.45%, while the medical services sector saw the largest decline of 2.12% [7][8] Industry Performance and Valuation - The pharmaceutical and biotechnology sector's recent one-month return was 2.94%, with a relative return of 3.63% against the CSI 300, ranking 10th among 31 primary sub-indices [9][18] - The current PE (TTM) for the pharmaceutical and biotechnology sector is 26.88 times, which is below the historical average of 30.99 times [14][15] Market Tracking - The chemical pharmaceutical sector has shown the largest growth over the past year, with a 16.51% increase, while the biological products sector has seen a decline of 11.36% [24][25] - The report highlights the potential for price increases in blood products due to supply and demand changes, particularly for domestic manufacturers [8] Focus on Individual Stocks - The report recommends focusing on specific companies in the blood products and high-end medical device sectors, such as Palin Bio, Tian Tan Bio, and Mindray Medical [8] - In the consumer healthcare sector, companies like Aier Eye Hospital and Yifeng Pharmacy are highlighted as potential beneficiaries of government stimulus policies [8] Industry and Company Dynamics - Recent policy developments include the approval of new medical service pricing for brain-computer interface technologies, indicating a growing focus on innovative medical solutions [40] - The report notes significant recent approvals for various pharmaceutical products, including those from companies like Jingxin Pharmaceutical and Antu Bio [41]

Summary of the Conference Call for Boya Biological Company Overview - **Company**: Boya Biological - **Focus**: Blood products, with a strategic emphasis on expanding production and market presence Key Points and Arguments Financial Performance - **Total Revenue**: 1.735 billion CNY, a year-on-year decrease primarily due to the divestiture of Tianan Pharmaceutical and Fudan Pharmaceutical [3] - **Blood Products Revenue**: 1.514 billion CNY, a year-on-year increase of 4.32%, driven by significant sales growth in prothrombin complex and factor VIII [3] - **Operating Profit**: 397 million CNY, a year-on-year increase of 67.18%, attributed to a lower base from the previous year [3] - **Return on Equity**: Increased by 2.08 percentage points to 5.36% [3] Business Expansion and Acquisitions - **Acquisition**: Successfully acquired 100% of the shares of Roche in Hong Kong, adding a production license and four plasma collection stations, bringing the total to 21 stations across seven provinces [5] - **Plasma Collection**: Achieved 630.6 tons of plasma collection, a year-on-year increase of 10.4%, with the main collection unit growing by 11.7%, surpassing industry averages [5] Product Development and Market Strategy - **Product Sales**: Strong performance in fibrinogen, with PCC and factor VIII exceeding sales targets, and PCC holding the third-largest market share [6] - **International Expansion**: Registered a new immunoglobulin product in Pakistan, indicating a strategic move towards international markets [6] Major Projects - **Smart Factory Project**: Progressing as planned, with the main structure completed and equipment installation ongoing, expected to commence production by the end of 2025, with financial impacts anticipated post-2027 [7][15] Industry Dynamics - **Supply and Demand**: Industry supply pressures have eased, with balanced demand for protein products, although competition for factor products may intensify [10] - **Collective Procurement Strategy**: Actively participating in Guangdong's collective procurement, monitoring policy changes closely [10] Future Projections - **Plasma Collection Goals for 2025**: Expected to exceed 700 tons, with a growth rate of over 10% [3][17] - **New Product Launches**: Anticipated rapid market uptake for new products expected to launch in Q3 2025 [9] Regulatory and Market Considerations - **Regulatory Changes**: Ongoing discussions regarding potential revisions to blood product management regulations, which could significantly impact the industry [20] - **Market Strategy Adjustments**: Focus on regional market penetration, particularly in East China, to optimize existing production capacity [21] Integration and Collaboration - **Sales Team Integration**: Ongoing integration of sales teams from Roche and Boya, aiming for enhanced market coverage and synergy [19] - **Technical Collaborations**: Engaging in technical cooperation with Central Asian countries to expand market reach and capabilities [17] Investment and Future Outlook - **Investment Plans**: Continued focus on core business and strategic acquisitions to enhance market position and operational efficiency [24] - **Long-term Growth Strategy**: Emphasis on technological innovation and market competitiveness to ensure sustainable growth [26] Additional Important Insights - **Market Potential in New Regions**: Significant growth potential identified in Anhui and Inner Mongolia, with strategic plans to address local concerns and enhance operational trust [22] - **Impact of Economic Conditions**: Despite macroeconomic pressures, the company has maintained a strong performance trajectory [11]

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index within the next six months [10]. Core Insights - The pharmaceutical sector showed a performance increase of +0.86% on March 18, 2025, outperforming the CSI 300 index by 0.59 percentage points, ranking fourth among 31 sub-industries in the Shenwan classification [4]. - Avidity's investigational therapy, delpacibart zotadirsen (del-zota), demonstrated unprecedented efficacy in protein expression during its Phase 1/2 clinical trial, with significant increases in skeletal muscle delivery and protein generation [5]. - The report highlights the performance of various sub-sectors, with medical research outsourcing (+5.56%) and hospitals (+1.34%) leading, while medical devices (+0.09%) and vaccine sectors (+0.27%) lagged behind [4]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine production: No rating - Biopharmaceutical II: Neutral - Other pharmaceutical sectors: Neutral [3]. Recommended Companies and Ratings - The report does not specify individual company ratings but emphasizes the overall positive outlook for the pharmaceutical industry [3].

Group 1 - The Ministry of Transport, National Development and Reform Commission, and Ministry of Finance support the scrapping and updating of old commercial vehicles that meet National III and IV emission standards, providing differentiated subsidies for early scrapping and purchasing new vehicles [2] - Xiaomi Group has raised its 2025 annual delivery target for electric vehicles to 350,000 units from the previous target of 300,000 units, indicating progress in production capacity [5] - The new stock N Hongjing listed on the ChiNext surged 282% on its debut, making it the most profitable new stock of the year with a profit of 59,100 yuan per lot [6] Group 2 - China Unicom reported a 10.5% year-on-year increase in net profit for 2024, with total revenue of 389.59 billion yuan, a 4.6% increase [11] - Daodaoquan achieved a net profit growth of 133.5% year-on-year for 2024, despite a 15.12% decline in revenue, and plans to distribute a cash dividend of 1.28 yuan per 10 shares [12] - Fuyou Glass reported a 33.2% increase in net profit for 2024, with revenue of 39.252 billion yuan, a growth of 18.37%, and plans to distribute a cash dividend of 1.8 yuan per share [14]

Financial Performance - The company's operating revenue for 2024 was ¥1,734,904,402.71, a decrease of 34.58% compared to ¥2,651,979,506.66 in 2023[17]. - Net profit attributable to shareholders for 2024 was ¥396,991,588.69, an increase of 67.18% from ¥237,465,593.87 in 2023[17]. - The net profit after deducting non-recurring gains and losses was ¥301,566,307.78, up 110.77% from ¥143,075,746.77 in 2023[17]. - The total assets at the end of 2024 reached ¥8,401,144,768.99, reflecting a growth of 7.31% from ¥7,828,900,301.89 at the end of 2023[17]. - The company reported a weighted average return on equity of 5.36%, an increase of 2.08 percentage points from 3.28% in 2023[17]. - The company achieved total operating revenue of ¥1,734,904,402.71, a decrease of 34.58% compared to the same period last year[51]. - Blood product business revenue reached ¥1,473,929,966.08, a slight increase of 0.86% year-on-year[52]. - The company reported a significant drop in sales for diabetes medication, with a 100% decrease in both sales and production volumes[71]. - The company reported a total revenue of 1,305.81 million for the fiscal year 2024[158]. Dividend Distribution - The company plans to distribute a cash dividend of 1.60 RMB per 10 shares, totaling 161,359,596.16 RMB, which represents 40.65% of the net profit attributable to shareholders for 2024[4]. - The total number of shares for the dividend distribution is 504,248,738 shares, with a total cash distribution of 80,679,798.08 RMB for the first half of 2024[4]. - The cash dividend for the entire year is projected to be 3.20 yuan (including tax) per 10 shares, amounting to a total of 1,613,595,961.60 yuan (including tax), which represents 40.65% of the net profit attributable to shareholders[181]. - The total number of shares for the cash dividend distribution is 504,248,738 shares, with no stock bonus or capital reserve conversion[179]. Operational and Market Insights - The blood products market in China is projected to reach ¥600 billion in 2024, with an expected compound annual growth rate of 11.6% from 2022 to 2027[28]. - The industry saw a 10.9% year-on-year increase in plasma collection volume, totaling 13,400 tons in 2024[29]. - The company is actively expanding its plasma collection stations, with 3 new stations approved and 17 additional operational stations in 2024[29]. - The competitive landscape in the blood products sector is intensifying, with multiple new products approved for market entry, leading to potential oversupply and price declines[29]. - The company reported a plasma collection volume of 630.6 tons in 2024, representing a year-on-year increase of 10.4%[32]. - The company is focusing on enhancing production processes and quality management to ensure stable product yield and compliance rates[35]. - The company aims to become a world-class blood product enterprise while gradually stabilizing and divesting its non-blood product business[34]. Research and Development - The company is committed to increasing R&D investment and optimizing product structure to maintain competitive advantages in the industry[32]. - The company has a robust R&D pipeline with over 200 patents and ongoing projects in various therapeutic areas, including high-concentration immunoglobulin and gene therapy[66]. - The company is in the process of clinical trials for several new products, including IVIG and C1 esterase inhibitors, aiming to enhance its product line and profitability[80]. - The company plans to launch new products, including a new formulation of human prothrombin complex, expected to be listed in 2025[47]. - The company is focusing on technological innovation, with projects like "membrane separation technology" being recognized as major research projects for 2024[47]. Governance and Compliance - The company has a comprehensive governance structure with all board members present for the report's approval[3]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its forward-looking statements[3]. - The company is committed to maintaining transparency and accuracy in its financial reporting, as stated by its management team[3]. - The company has established a market value management system and valuation enhancement plan to protect investor interests and improve corporate governance[131]. - The company has optimized its governance structure and internal control systems to enhance operational compliance and protect investor rights[1]. Environmental and Social Responsibility - The company adheres strictly to multiple environmental protection laws and standards, ensuring compliance in its operations[190]. - The company has established a comprehensive environmental management system to ensure compliance with pollution discharge standards[196]. - The company is actively pursuing new product launches and production line upgrades to enhance operational efficiency and market competitiveness[193]. - The company has set a target to reduce volatile organic compounds emissions to below 0.07 mg/m³ by 2024[198]. - The company is investing in new technology to enhance emission control systems, aiming for a 30% reduction in overall emissions by 2025[198]. Challenges and Risks - The company is facing challenges in the chemical drug sector, with ongoing losses due to slow project development and competitive pricing pressures[39]. - The company faces risks related to raw material supply, particularly the availability of human plasma, which is crucial for blood product production, and plans to expand plasma collection stations to mitigate this risk[125]. - New product development poses risks due to lengthy processes and market demand uncertainties; the company will conduct comprehensive market research before project initiation to ensure alignment with market needs[126]. - There is a risk of goodwill impairment following the acquisition of Green Cross (China), which the company plans to address by enhancing marketing strategies and expanding market share[129]. Shareholder Engagement - The company held its first temporary shareholders' meeting of 2024 on January 12, with an investor participation rate of 47.21%[145]. - The second temporary shareholders' meeting of 2024 took place on March 21, with a participation rate of 45.21%[145]. - The annual shareholders' meeting for 2023 was held on April 12, 2024, with a participation rate of 42.33%[145]. - The company continues to engage shareholders actively, as evidenced by the participation rates in the various meetings held[145]. Personnel and Management - The company has a total of 2,903,400 shares held by a former vice chairman, with a reduction of 100,000 shares noted[147]. - The company has maintained a diverse board with independent directors nominated for the eighth board[148]. - The company’s management team has been strengthened with the appointment of new directors and executives, enhancing its operational capabilities[153]. - The company has implemented a performance management system for its management team, aiming to improve accountability and performance metrics[165]. - The company has a structured decision-making process for compensation, involving a nomination and remuneration committee[156].

Financial Performance Expectations - The company expects net profit attributable to shareholders to be between 38,000 and 48,000 thousand yuan, representing a year-on-year growth of 60.03% to 102.14% compared to 23,746 thousand yuan in the previous year[3]. - The net profit after deducting non-recurring gains and losses is projected to be between 28,374 and 38,374 thousand yuan, indicating a year-on-year increase of 98.32% to 168.22% from 14,307 thousand yuan last year[3]. - Basic earnings per share are expected to be between 0.75 and 0.95 yuan per share, compared to 0.47 yuan per share in the previous year[3]. Revenue and Operational Highlights - The main reason for the performance change is the increase in revenue from blood products and the low base effect from goodwill impairment and other asset impairment in the previous year[5]. - The company achieved a plasma collection volume of 522.04 tons from 16 operating plasma stations, marking an 11.71% year-on-year growth[5]. Non-Recurring Gains and Losses - The estimated impact of non-recurring gains and losses on net profit is approximately 9,626 thousand yuan[5]. Audit and Reporting - The financial data in this earnings forecast has not been audited by a registered accounting firm[4]. - The specific data will be detailed in the company's 2024 annual report[7]. Investment Advisory - Investors are advised to make cautious decisions and be aware of investment risks[7]. - The earnings forecast period is from January 1, 2024, to December 31, 2024[3].

Financial Performance - Q3 2024 revenue was CNY 349,372,113.05, a decrease of 46.21% year-over-year, while total revenue for the first nine months was CNY 1,245,107,779.60, down 43.16% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was CNY 96,733,318.26, a decline of 29.98% year-over-year, with a nine-month total of CNY 412,703,629.27, down 11.07%[2]. - Operating revenue for the first nine months of 2024 was approximately ¥1.25 billion, a decrease of 43.16% compared to ¥2.19 billion in the same period of 2023[7]. - Total operating revenue for Q3 2024 was CNY 1,245,107,779.60, a decrease of 43.2% compared to CNY 2,190,398,869.51 in the same period last year[20]. - The net profit for Q3 2024 was CNY 412.43 million, a decrease of 13.00% compared to CNY 474.09 million in Q3 2023[21]. - The total profit for Q3 2024 was CNY 480.43 million, compared to CNY 575.20 million in Q3 2023, a decline of 16.49%[21]. Revenue and Costs - Total operating costs for Q3 2024 were CNY 853,438,255.57, down 51.2% from CNY 1,749,069,896.51 year-over-year[20]. - Operating costs for the same period were approximately ¥415 million, down 62.07% from ¥1.09 billion year-on-year[7]. - Cash received from sales of goods and services was approximately ¥1.19 billion, a decline of 47.40% compared to ¥2.25 billion in 2023[7]. - Cash paid for purchasing goods and services was approximately ¥334 million, down 63.82% from ¥923 million year-on-year[7]. - Sales expenses decreased by 39.71% to approximately ¥274 million from ¥454 million in the previous year[7]. - The company reported a significant reduction in sales expenses, which decreased to CNY 273,785,234.14 from CNY 454,124,674.39, a decline of 39.6%[20]. Assets and Equity - Total assets as of September 30, 2024, were CNY 8,157,947,458.71, reflecting a 4.20% increase from the end of the previous year[2]. - Shareholders' equity increased to CNY 7,581,179,585.65, up 3.57% from the end of the previous year[2]. - The company's total equity attributable to shareholders increased to CNY 7,581,179,585.65, compared to CNY 7,319,750,577.78, marking a growth of 3.6%[19]. - The company’s total current assets increased to RMB 6.59 billion from RMB 6.43 billion at the beginning of the period, reflecting a growth of approximately 2.5%[17]. - The company’s inventory rose to RMB 627.58 million, up from RMB 556.94 million, indicating an increase of about 12.7%[17]. - The company’s cash and cash equivalents at the end of the period were RMB 1.99 billion, compared to RMB 1.96 billion at the beginning, showing a slight increase of 1.4%[17]. Cash Flow - Cash flow from operating activities for the first nine months was CNY 262,408,653.79, a significant decrease of 50.08% compared to the same period last year[2]. - Cash flow from operating activities decreased to CNY 262.41 million in Q3 2024, compared to CNY 525.71 million in Q3 2023, a drop of 50.16%[23]. - The company reported a net cash inflow of approximately ¥109 million from the disposal of subsidiaries, a significant increase of 200.18% compared to ¥36 million in the previous year[7]. - The company recorded a net cash outflow from investment activities of CNY 53.56 million in Q3 2024, an improvement from a net outflow of CNY 519.77 million in Q3 2023[23]. - Cash flow from financing activities showed a net outflow of CNY 170.21 million in Q3 2024, compared to a net outflow of CNY 193.63 million in the same period last year, indicating a reduction of 12.56%[24]. Investments and Acquisitions - The company plans to increase investment in smart factory projects, with cash payments for fixed assets rising by 59.99% to approximately ¥119 million[7]. - The company has made a cash payment of ¥182 million related to the acquisition of Green Cross, indicating ongoing market expansion strategies[7]. - The company completed the acquisition of 100% equity in Green Cross Hong Kong Holdings Limited for RMB 1.82 billion, indirectly acquiring Green Cross (China) Biological Products Co., Ltd.[11]. Plasma Collection and Production - The blood products business generated revenue of CNY 1,089,481,025.84 for the first nine months, an increase of 0.39% year-over-year, driven by higher sales of prothrombin complex and factor VIII[3]. - The company collected 387.44 tons of raw plasma in the first nine months, representing a 12.39% increase compared to the previous year, due to improved local donation environments and service quality[3]. - The company’s subsidiary, Taihe Plasma Station, and Leping Plasma Station received the Single Plasma Collection License, enhancing the raw plasma supply capacity.[12]. - The company is actively advancing the construction of its intelligent blood product factory, with major structural work completed, marking a new phase in the project.[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,602, indicating a stable shareholder base[8]. - The company’s cash dividend distribution for the first half of 2024 is set at RMB 1.60 per 10 shares, totaling RMB 80.68 million, which accounts for 25.53% of the net profit attributable to shareholders for the same period.[14]. Research and Development - Research and development expenses for Q3 2024 amounted to CNY 47,378,915.31, slightly down from CNY 48,042,073.01 in the previous year[20].

Financial Performance - The company's operating revenue for the reporting period was ¥895,735,666.55, a decrease of 41.87% compared to ¥1,540,872,254.12 in the same period last year[13]. - Net profit attributable to shareholders was ¥315,970,311.01, down 3.05% from ¥325,918,480.96 year-on-year[13]. - The net cash flow from operating activities was ¥211,660,633.61, reflecting a decline of 46.17% compared to ¥393,183,884.50 in the previous year[13]. - The total assets at the end of the reporting period amounted to ¥8,023,345,740.98, representing an increase of 2.48% from ¥7,828,900,301.89 at the end of the previous year[13]. - The company achieved total operating revenue of ¥895,735,666.55, a decrease of 41.87% compared to the same period last year[34]. - The blood products business generated operating income of ¥790,132,233.58, an increase of 3.64% year-on-year, primarily due to increased sales of PCC and factor VIII[34]. - The biochemical drug business reported operating income of ¥101,578,802.9, a decrease of 44.98% year-on-year, impacted by procurement policies[34]. - The company reported a net profit attributable to shareholders of ¥315,970,311.01, a decrease of 3.05% year-on-year, mainly due to the exclusion of certain subsidiaries from the consolidated financial statements[34]. - The company reported a significant increase of 698.86% in cash flow from investment activities, totaling approximately ¥1.23 billion, due to increased financial management cash flow and equity transfer proceeds[43]. - The company’s total comprehensive income for the first half of 2024 was ¥319,150,548.57, down from ¥552,349,969.28 in the same period of 2023, indicating a decline of about 42.2%[128]. Dividend Distribution - The company plans to distribute a cash dividend of 1.60 RMB per 10 shares, based on a total of 504,248,738 shares[2]. - The cash dividend distribution represents 100% of the total distributable profit, amounting to approximately 2.70 billion RMB[73]. Acquisitions and Subsidiaries - The company has fully acquired 100% equity of Green Cross (Hong Kong) in July 2024[6]. - The company completed the acquisition of 100% equity in Green Cross Hong Kong Holdings Limited for RMB 1.82 billion, indirectly acquiring Green Cross (China) Biological Products Co., Ltd.[110]. - The company has a total of 9 wholly-owned subsidiaries involved in blood plasma collection[6]. - The company’s subsidiary, New Biopharmaceuticals, reported a net profit of RMB 8,003,375.89, while another subsidiary, Boya Xinhao, reported a net loss of RMB 11,315,816.01[65]. Production and Operations - The company collected 246.89 tons of raw plasma during the reporting period, marking a year-on-year increase of 14.63%[18]. - The company has 16 single plasma collection stations, with two new stations obtaining licenses in July 2024[18]. - The company achieved a total of 189,814 bottles of human albumin (5g/bottle) in the first half of 2024, representing an 18.7% increase compared to 159,907 bottles in the same period of 2023[22]. - The production of human immunoglobulin (5g/bottle) increased by 6.6%, with 107,614 bottles produced in the first half of 2024 compared to 100,944 bottles in the same period of 2023[22]. - The production of human coagulation factor VIII decreased by 74.8%, with only 11,301 bottles produced in the first half of 2024 compared to 44,806 bottles in the same period of 2023[23]. - The company has established a complete standardized business management system for plasma collection, covering all aspects from blood source registration to plasma storage and transportation[27]. - The company is focused on becoming a world-class blood products enterprise while gradually stabilizing and divesting non-blood product businesses[19]. Research and Development - The company aims to enhance its research and development efforts to diversify its product line and improve plasma utilization rates[18]. - The company is actively pursuing R&D in blood products, with key projects such as IVIG and vWF in clinical trial stages, and plans to apply for drug registration certificates[30]. - The company has established multiple R&D platforms and partnerships with universities and research institutions to strengthen its innovation capabilities[30]. - The company focuses on biochemical drug research and development, with a complete product structure and a leading market position in core products such as bone peptide series and oxytocin series[23]. Financial Position - Cash and cash equivalents increased to ¥3,252,295,313.33, representing 40.54% of total assets, up from 25.05% last year, a change of 15.49%[46]. - The company reported a total investment of ¥2,881,673,432.95 for the reporting period, a decrease of 15.07% compared to ¥3,393,069,430.69 in the same period last year, mainly due to reduced purchases of financial products[50]. - The company’s long-term borrowings were reclassified to current liabilities, totaling ¥22,961,005.13, reflecting a significant increase from ¥907,054.30 last year[47]. - The company’s inventory stood at ¥577,321,177.61, accounting for 7.20% of total assets, showing no significant change from the previous year[46]. - The company’s total liabilities increased to ¥3,200,000,000, reflecting a rise of 5% compared to the previous period[120]. Environmental Compliance - The company has received environmental impact report approvals for all existing projects, ensuring compliance with environmental regulations[76]. - Huaren Boya Bio achieved a total pollutant discharge of 3.0025 tons for COD, well below the approved limit of 13.36 tons[77]. - The company has implemented pollution prevention measures as outlined in their environmental impact reports, ensuring minimal environmental impact[76]. - All companies under Huaren Boya Bio have been classified as non-key pollutant discharge units by environmental authorities, reflecting their commitment to environmental responsibility[75]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[2]. - The company faces risks related to the supply of raw materials, specifically human plasma, which is tightly regulated and affects production capacity[65]. - The company will conduct comprehensive market research before launching new products to mitigate risks associated with product development and ensure alignment with market demand[66]. - The company has established a robust quality management system to control product quality risks, which is critical for maintaining brand reputation and market position[66]. Shareholder Information - The total number of shares after the recent changes is 504,248,738, with 15.53% being restricted shares and 84.47% being unrestricted shares[112]. - The largest shareholder, China Resources Pharmaceutical Group, holds 29.28% of the shares, totaling 147,640,553[113]. - The report indicates that there were no changes in the number of shares held by the top shareholders during the reporting period[113]. Corporate Governance - The half-year financial report was not audited, and there were no significant guarantees or major contracts affecting the company's profit during the reporting period[95][109]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[74]. - There were no significant lawsuits or arbitration matters during the reporting period[96].

Financial Performance - The company's revenue for Q1 2024 was ¥448,452,537.26, a decrease of 44.36% compared to ¥805,928,136.64 in the same period last year[5] - Net profit attributable to shareholders for Q1 2024 was ¥152,024,886.81, down 10.74% from ¥170,317,490.97 in the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥127,306,750.41, a decrease of 7.63% from ¥137,815,331.11 year-on-year[5] - Basic and diluted earnings per share for Q1 2024 were both ¥0.30, a decline of 11.76% from ¥0.34 in the previous year[5] - The net profit for the period is reported at ¥151,760,842.43, compared to ¥174,373,215.65 in the previous period, showing a decrease of about 12.92%[27] - The total comprehensive income amounted to 151,760,842.43, down from 174,373,215.65, indicating a decrease of about 13.0%[28] - Basic and diluted earnings per share were both 0.30, compared to 0.34 in the previous period, reflecting a decline of approximately 11.8%[28] - The company reported a net profit of ¥151,760,842.43 for the current period, down 14.5% from ¥177,373,215.65 in the previous period[39] Cash Flow and Assets - The net cash flow from operating activities was ¥123,871,710.13, down 44.37% from ¥222,678,836.22 in the same quarter last year[5] - Cash flow from operating activities was 410,436,128.44, significantly lower than 782,399,226.54, representing a decrease of about 47.5%[28] - The company's cash and cash equivalents at the end of Q1 2024 amount to ¥1,860,435,345.29, down from ¥1,961,478,737.03 at the beginning of the period, representing a decrease of approximately 5.14%[12] - The net increase in cash and cash equivalents was -105,345,193.69, contrasting with a positive increase of 179,436,811.37 in the previous period[31] - Total assets at the end of Q1 2024 were ¥7,992,850,470.88, an increase of 2.09% from ¥7,828,900,301.89 at the end of the previous year[5] - The total current assets rose to 6,612,770,411.54 from 6,427,633,042.37, indicating an increase of about 2.9%[36] - The total non-current assets decreased to 1,380,080,059.34 from 1,401,267,259.52, reflecting a decline of approximately 1.5%[36] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,406[10] - The largest shareholder, China Resources Pharmaceutical Group, holds 29.28% of shares, totaling 147,640,553 shares[10] - The number of shares held by the top ten shareholders includes significant stakes from institutional investors, with the second-largest shareholder holding 11.31%[10] Operating Costs and Expenses - The company reported a significant decrease in operating costs, which were ¥144,457,836.40, down 65.93% from ¥424,061,104.31 year-on-year[7] - Total operating costs for the current period were ¥301,267,242.96, down 52.5% from ¥634,659,929.03 in the previous period[39] - Research and development expenses increased by 90.36% to ¥19,006,039.85 compared to ¥9,984,394.66 in the same period last year[7] - Research and development expenses increased to ¥19,006,039.85, up 90.5% from ¥9,984,394.66 in the previous period[39] Liabilities and Equity - Total liabilities amounted to ¥520,264,129.08, an increase of 2.3% from ¥508,074,802.52 in the previous period[39] - Shareholders' equity attributable to the parent company was ¥7,471,775,464.59, up 2.08% from ¥7,319,750,577.78 at the end of last year[5] - Total equity attributable to shareholders reached ¥7,471,775,464.59, up 2.1% from ¥7,319,750,577.78 in the previous period[39] Non-Recurring Gains and Losses - The company has no significant changes in non-recurring gains and losses that would affect its financial reporting[19] - The company has not reclassified any non-recurring gains and losses as regular gains and losses[19]

2023 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：300294 证券简称：博雅生物 公告编号：2024-038 华润博雅生物制药集团股份有限公司 特别提示： 1、公司本次实施的利润分配方案为：以股份总数504,248,738股为基数，向 全体股东每10股派发现金红利3.000000元（含税）。公司本次现金分红的总金额 = 实 际 参 与 分 配 的 股 本 ×分配比例 =504,248,738 股 ×3.000000 元 ÷10 股 =151,274,621.40元。自分配方案披露至实施期间公司股本总额未发生变化，若发 生变化公司将按照现金分红总额不变的原则对分配比例进行调整。 2、本次权益分派方案实施后，按公司总股本折算每股现金分红=本次实际现 金分红总额/公司总股本=151,274,621.40/504,248,738=0.300000元。因此，在保证 本次权益分派方案不变的前提下，公司2023年年度权益分派实施后的除权除息价 格按照上述原则及计算方式执行，即本次权益分派实施后的除权除息价格=除权 除息日前收盘价-按总股 ...